



Safety Data Sheet acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

1 Identification

- **Product identifier**
- **Trade name:** Dabigatran-13C-d3
- **Article number:** 35705
- **CAS Number:**
211914-51-1
- **Application of the substance / the mixture**
This product is for research use - Not for human or veterinary diagnostic or therapeutic use. It is the responsibility of the purchaser to determine suitability for other applications.
- **Details of the supplier of the safety data sheet**
- **Manufacturer/Supplier:**
Cayman Chemical Co.
1180 E. Ellsworth Rd.
Ann Arbor, MI 48108
USA
- **Information department:** Product safety department
- **Emergency telephone number:**
During normal opening times: +1 (734) 971-3335
US/CANADA: 800-424-9300
Outside US/CANADA: 703-741-5970

2 Hazard(s) identification

- **Classification of the substance or mixture**



GHS07

Acute Tox. 4 H302 Harmful if swallowed.
Skin Irrit. 2 H315 Causes skin irritation.
Eye Irrit. 2A H319 Causes serious eye irritation.
STOT SE 3 H335 May cause respiratory irritation.

- **Label elements**
- **GHS label elements**

The substance is classified and labeled according to the Globally Harmonized System (GHS).

(Contd. on page 2)

US

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 1)

· Hazard pictograms



GHS07

· Signal word Warning

· Hazard-determining components of labeling:

Dabigatran

· Hazard statements

H302 Harmful if swallowed.

H315 Causes skin irritation.

H319 Causes serious eye irritation.

H335 May cause respiratory irritation.

· Precautionary statements

P261 Avoid breathing dust/fume/gas/mist/vapors/spray

P264 Wash thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves / eye protection / face protection.

P301+P312 If swallowed: Call a poison center/doctor if you feel unwell.

P330 Rinse mouth.

P302+P352 If on skin: Wash with plenty of water.

P321 Specific treatment (see on this label).

P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P332+P313 If skin irritation occurs: Get medical advice/attention.

P362+P364 Take off contaminated clothing and wash it before reuse.

P337+P313 If eye irritation persists: Get medical advice/attention.

P403+P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

P501 Dispose of contents/container in accordance with local/regional/national/international regulations.

· Classification system:

· NFPA ratings (scale 0 - 4)



Health = 2

Fire = 0

Reactivity = 0

· HMIS-ratings (scale 0 - 4)



HEALTH 2 Health = 2

FIRE 0 Fire = 0

REACTIVITY 0 Reactivity = 0

· Other hazards

· Results of PBT and vPvB assessment

· PBT: Not applicable.

· vPvB: Not applicable.

US

(Contd. on page 3)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 2)

3 Composition/information on ingredients

- **Chemical characterization: Substances**
- **CAS No. Description**
211914-51-1 Dabigatran

4 First-aid measures

- **Description of first aid measures**
- **General information:**
Immediately remove any clothing soiled by the product.
Symptoms of poisoning may even occur after several hours; therefore medical observation for at least 48 hours after the accident.
- **After inhalation:** In case of unconsciousness place patient stably in side position for transportation.
- **After skin contact:** Immediately wash with water and soap and rinse thoroughly.
- **After eye contact:**
Rinse opened eye for several minutes under running water. If symptoms persist, consult a doctor.
- **After swallowing:** Immediately call a doctor.
- **Information for doctor:**
- **Most important symptoms and effects, both acute and delayed**
May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects.
No further relevant information available.
- **Indication of any immediate medical attention and special treatment needed**
No further relevant information available.

5 Fire-fighting measures

- **Extinguishing media**
- **Suitable extinguishing agents:**
Use fire fighting measures that suit the environment.
A solid water stream may be inefficient.
- **Special hazards arising from the substance or mixture** No further relevant information available.
- **Advice for firefighters**
- **Protective equipment:** No special measures required.

6 Accidental release measures

- **Personal precautions, protective equipment and emergency procedures** Not required.
- **Environmental precautions:** Do not allow to enter sewers/ surface or ground water.
- **Methods and material for containment and cleaning up:**
Dispose contaminated material as waste according to item 13.
Ensure adequate ventilation.
- **Reference to other sections**
See Section 7 for information on safe handling.
See Section 8 for information on personal protection equipment.
See Section 13 for disposal information.
- **Protective Action Criteria for Chemicals**

- **PAC-1:**

Substance is not listed.

(Contd. on page 4)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 3)

· **PAC-2:**

Substance is not listed.

· **PAC-3:**

Substance is not listed.

7 Handling and storage

- **Handling:**
- **Precautions for safe handling** Ensure good ventilation/exhaustion at the workplace.
- **Information about protection against explosions and fires:** No special measures required.
- **Conditions for safe storage, including any incompatibilities**
- **Storage:**
- **Requirements to be met by storerooms and receptacles:** No special requirements.
- **Information about storage in one common storage facility:** Not required.
- **Further information about storage conditions:** Keep receptacle tightly sealed.
- **Specific end use(s)** No further relevant information available.

8 Exposure controls/personal protection

- **Additional information about design of technical systems:** No further data; see item 7.
- **Control parameters**
- **Components with limit values that require monitoring at the workplace:** Not required.
- **Additional information:** The lists that were valid during the creation were used as basis.
- **Exposure controls**
- **Personal protective equipment:**
- **General protective and hygienic measures:**
Keep away from foodstuffs, beverages and feed.
Immediately remove all soiled and contaminated clothing.
Wash hands before breaks and at the end of work.
Avoid contact with the eyes and skin.
- **Breathing equipment:**
In case of brief exposure or low pollution use respiratory filter device. In case of intensive or longer exposure use respiratory protective device that is independent of circulating air.
- **Protection of hands:**



Protective gloves

The glove material has to be impermeable and resistant to the product/ the substance/ the preparation. Due to missing tests no recommendation to the glove material can be given for the product/ the preparation/ the chemical mixture.

Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

· **Material of gloves**

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer.

· **Penetration time of glove material**

The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

(Contd. on page 5)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 4)

· Eye protection:



Tightly sealed goggles

9 Physical and chemical properties

· Information on basic physical and chemical properties

· General Information

· Appearance:

Form:

Solid

Color:

Not determined.

· Odor:

Characteristic

· Structural Formula

C24[13C]H22D3N7O3

· Molecular Weight

475.5 g/mol

· Odor threshold:

Not determined.

· pH-value:

Not applicable.

· Change in condition

Melting point/Melting range:

Undetermined.

Boiling point/Boiling range:

Undetermined.

· Flash point:

Not applicable.

· Flammability (solid, gaseous):

Product is not flammable.

· Decomposition temperature:

Not determined.

· Auto igniting:

Not determined.

· Danger of explosion:

Product does not present an explosion hazard.

· Explosion limits:

Lower:

Not determined.

Upper:

Not determined.

· Vapor pressure:

Not applicable.

· Density:

Not determined.

· Relative density

Not determined.

· Vapor density

Not applicable.

· Evaporation rate

Not applicable.

· Solubility in / Miscibility with

Water:

Soluble.

· Partition coefficient (n-octanol/water):

Not determined.

· Viscosity:

Dynamic:

Not applicable.

Kinematic:

Not applicable.

VOC content:

0.00 %

Solids content:

100.0 %

(Contd. on page 6)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 5)

· Other information

No further relevant information available.

10 Stability and reactivity

- **Reactivity** No further relevant information available.
- **Chemical stability**
- **Thermal decomposition / conditions to be avoided:**
No decomposition if used according to specifications.
- **Possibility of hazardous reactions** No dangerous reactions known.
- **Conditions to avoid** No further relevant information available.
- **Incompatible materials:** Strong oxidizing agents
- **Hazardous decomposition products:** Carbon oxides. Nitrogen oxides (NOx)

11 Toxicological information

- **Information on toxicological effects**
- **Acute toxicity:**

- **LD/LC50 values that are relevant for classification:**

ATE (Acute Toxicity Estimate)		
Oral	LD50	500 mg/kg

- **Primary irritant effect:**
- **on the skin:** Irritant to skin and mucous membranes.
- **on the eye:** Irritating effect.
- **Sensitization:** No sensitizing effects known.
- **Additional toxicological information:**

- **Carcinogenic categories**

- **IARC (International Agency for Research on Cancer)**

Substance is not listed.

- **NTP (National Toxicology Program)**

Substance is not listed.

- **OSHA-Ca (Occupational Safety & Health Administration)**

Substance is not listed.

12 Ecological information

- **Toxicity**
- **Aquatic toxicity:** No further relevant information available.
- **Persistence and degradability** No further relevant information available.
- **Behavior in environmental systems:**
- **Bioaccumulative potential** No further relevant information available.
- **Mobility in soil** No further relevant information available.
- **Additional ecological information:**
- **General notes:**
Water hazard class 1 (Self-assessment): slightly hazardous for water
Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.

(Contd. on page 7)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 6)

- **Results of PBT and vPvB assessment**
- **PBT:** Not applicable.
- **vPvB:** Not applicable.
- **Other adverse effects** No further relevant information available.

13 Disposal considerations

- **Waste treatment methods**
- **Recommendation:**
Must not be disposed of together with household garbage. Do not allow product to reach sewage system.
- **Uncleaned packagings:**
- **Recommendation:** Disposal must be made according to official regulations.
- **Recommended cleansing agent:** Water, if necessary with cleansing agents.

14 Transport information

- | | |
|--|-----------------|
| · UN-Number | |
| · DOT, IMDG, IATA | not regulated |
| · UN proper shipping name | |
| · DOT, IMDG, IATA | not regulated |
| · Transport hazard class(es) | |
| · DOT, ADN, IMDG, IATA | |
| · Class | not regulated |
| · Packing group | |
| · DOT, IMDG, IATA | not regulated |
| · Environmental hazards: | Not applicable. |
| · Special precautions for user | Not applicable. |
| · Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code | Not applicable. |
| · UN "Model Regulation": | not regulated |

15 Regulatory information

- **Safety, health and environmental regulations/legislation specific for the substance or mixture**
No further relevant information available.
- **Sara**

· **Section 355 (extremely hazardous substances):**

Substance is not listed.

· **Section 313 (Specific toxic chemical listings):**

Substance is not listed.

· **TSCA (Toxic Substances Control Act):**

Substance is not listed.

(Contd. on page 8)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

(Contd. from page 7)

- **Hazardous Air Pollutants**

Substance is not listed.

- **Proposition 65**

- **Chemicals known to cause cancer:**

Substance is not listed.

- **Chemicals known to cause reproductive toxicity for females:**

Substance is not listed.

- **Chemicals known to cause reproductive toxicity for males:**

Substance is not listed.

- **Chemicals known to cause developmental toxicity:**

Substance is not listed.

- **Carcinogenic categories**

- **EPA (Environmental Protection Agency)**

Substance is not listed.

- **TLV (Threshold Limit Value)**

Substance is not listed.

- **NIOSH-Ca (National Institute for Occupational Safety and Health)**

Substance is not listed.

- **Chemical safety assessment:** A Chemical Safety Assessment has not been carried out.

16 Other information

All chemicals may pose unknown hazards and should be used with caution. This SDS applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomes contaminated, it may pose hazards not mentioned in this SDS. Cayman Chemical Company assumes no responsibility for incidental or consequential damages, including lost profits, arising from the use of these data. It shall be the user's responsibility to develop proper methods of handling and personal protection based on the actual conditions of use. While this SDS is based on technical data judged to be reliable, Cayman Chemical Company assumes no responsibility for the completeness or accuracy of the information contained herein.

- **Department issuing SDS:** Environment protection department.

- **Contact:** -

- **Date of preparation / last revision** 10/06/2021 / -

- **Abbreviations and acronyms:**

IMDG: International Maritime Code for Dangerous Goods

DOT: US Department of Transportation

IATA: International Air Transport Association

CAS: Chemical Abstracts Service (division of the American Chemical Society)

NFPA: National Fire Protection Association (USA)

HMIS: Hazardous Materials Identification System (USA)

VOC: Volatile Organic Compounds (USA, EU)

LC50: Lethal concentration, 50 percent

LD50: Lethal dose, 50 percent

PBT: Persistent, Bioaccumulative and Toxic

vPvB: very Persistent and very Bioaccumulative

NIOSH: National Institute for Occupational Safety

OSHA: Occupational Safety & Health

TLV: Threshold Limit Value

PEL: Permissible Exposure Limit

REL: Recommended Exposure Limit

Acute Tox. 4: Acute toxicity – Category 4

Skin Irrit. 2: Skin corrosion/irritation – Category 2

(Contd. on page 9)

Safety Data Sheet

acc. to OSHA HCS

Printing date 10/06/2021

Revision date 10/06/2021

Trade name: Dabigatran-13C-d3

Eye Irrit. 2A: Serious eye damage/eye irritation – Category 2A
STOT SE 3: Specific target organ toxicity (single exposure) – Category 3

(Contd. from page 8)

US